NNC0582 0001
Alternative Names: NN-6582; NNC0582-0001Latest Information Update: 24 Nov 2022
At a glance
- Originator Novo Nordisk
- Class Hepatoprotectants; Small interfering RNA
- Mechanism of Action Liver X receptor modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 14 Nov 2022 Phase-I clinical trials in Unspecified in Austria (SC) (NCT05624580)